← All Biontech SE filings

Biontech SE Form 4 insider transactions

NASDAQ
BNTX
Biontech SE
425: BioNTech to Acquire CureVac, Bolstering mRNA Oncology Pipeline and Manufacturing Capabilities
BioNTech SE has announced a definitive Purchase Agreement to acquire all shares of CureVac N.V., a strategic move aimed at strengthening its mRNA-based cancer immunotherapy programs and integrating CureVac's research and manufacturing site.
NASDAQ
BNTX
Biontech SE
425: BioNTech Moves to Acquire CureVac in $1.25 Billion mRNA Technology Expansion
BioNTech SE has announced its intent to acquire CureVac N.V. through an exchange offer valued at approximately $1.25 billion, aiming to bolster its mRNA capabilities and pipeline.
NASDAQ
BNTX
Biontech SE
425: BioNTech Initiates Formal Steps for Proposed Acquisition of CureVac Through Exchange Offer
BioNTech SE has filed pre-commencement communications with the SEC regarding its proposed acquisition of CureVac N.V. through an exchange offer, outlining the procedural steps and associated risks.
NASDAQ
BNTX
Biontech SE
425: BioNTech to Acquire CureVac in $1.25 Billion All-Stock Deal, Bolstering mRNA Oncology Pipeline
BioNTech SE announced a definitive agreement to acquire CureVac N.V. in an all-stock transaction valued at approximately $1.25 billion, aiming to significantly strengthen its mRNA-based cancer immunotherapy capabilities.